New Data for JAK Inhibitor-treatment and Pregnancy

Active inflammatory bowel disease during pregnancy increases the risk of adverse pregnancy outcome by two to five fold. In case of remission in IBD during pregnancy, the risk of adverse pregnancy outcome is similar to the non-IBD background population.
At UEGW Mette Juelsgaard present data from a global study new data for treatment with JAK-inhibitors, a group af drugs that cross the placenta from early pregnancy, regarding the risk of adverse pregnancy outcome after JAK-inhibitor exposure in pregnancy.